PHENOBARBITAL tablet

País: Estados Unidos

Idioma: inglés

Fuente: NLM (National Library of Medicine)

Ingredientes activos:

PHENOBARBITAL (UNII: YQE403BP4D) (PHENOBARBITAL - UNII:YQE403BP4D)

Disponible desde:

McKesson Contract Packaging

Designación común internacional (DCI):

PHENOBARBITAL

Composición:

PHENOBARBITAL 15 mg

tipo de receta:

PRESCRIPTION DRUG

Estado de Autorización:

unapproved drug other

Ficha técnica

PHENOBARBITAL- PHENOBARBITAL TABLET
MCKESSON CONTRACT PACKAGING
_Disclaimer: This drug has not been found by FDA to be safe and
effective, and this labeling has not been_
_approved by FDA. For further information about unapproved drugs,
click here._
----------
PHENOBARBITAL TABLETS USP
PHENOBARBITAL TABLETS, USP C R ONLY
DESCRIPTION:
Phenobarbital is a barbituric acid derivative for oral administration
and occurs as a white, odorless,
slightly bitter powder that is soluble in chloroform, freely soluble
in alcohol or ether, and slightly
soluble in water. Its saturated solution has a pH of about 5.6.
Chemically, it is 5-ethyl-5-
phenylbarbituric acid with the molecular formula C
H N O (232.24). The structural formula is as
follows:
Each phenobarbital tablet contains 15 mg, 30 mg, 60 mg or 100 mg of
phenobarbital. Inactive
ingredients are as follows:
15 MG, 30 AND 60 MG: Calcium Stearate, Colloidal Silicon Dioxide, Corn
Starch, and Microcrystalline
Cellulose.
100 MG: Anhydrous Lactose, Colloidal Silicon Dioxide, Corn Starch,
Docusate Sodium, Lactose
Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, and
Sodium Starch Glycolate.
CLINICAL PHARMACOLOGY:
Phenobarbital, a long-acting barbiturate, is a central nervous system
depressant. In ordinary doses, the
drug acts as a sedative and anticonvulsant. Its onset of action occurs
within 30 minutes, and the duration
of action ranges from 5 to 6 hours. It is detoxified in the liver.
INDICATION AND USAGE:
Phenobarbital is indicated for use as a sedative or anticonvulsant.
CONTRAINDICATIONS:
Phenobarbital is contraindicated in patients who are hypersensitive to
barbiturates. In such patients,
severe hepatic damage can occur from ordinary doses and is usually
associated with dermatitis and
involvement of parenchymatous organs. A personal or familial history
of acute intermittent porphyria
represents one of the few absolute contraindications to the use of
barbiturates. Phenobarbital is also
contraindicated in patients with marked impairment of liver function,
or respir